Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Optimal asthma control, starting with high doses sf inhaled budesonide
Autore:
Reddel, HK; Jenkins, CR; Marks, GB; Ware, SI; Xuan, W; Salome, CM; Badcock, CA; Woolcock, AJ;
Indirizzi:
Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia Royal Prince Alfred Hosp Camperdown NSW Australia 2050 SW 2050, Australia Univ Sydney, Camperdown, NSW, Australia Univ Sydney Camperdown NSW Australia Sydney, Camperdown, NSW, Australia AstraZeneca Australia, N Ryde, NSW, Australia AstraZeneca Australia N Ryde NSW Australia ralia, N Ryde, NSW, Australia
Titolo Testata:
EUROPEAN RESPIRATORY JOURNAL
fascicolo: 2, volume: 16, anno: 2000,
pagine: 226 - 235
SICI:
0903-1936(200008)16:2<226:OACSWH>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PEAK EXPIRATORY FLOW; LONG-TERM TREATMENT; CLINICAL ASTHMA; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL RESPONSIVENESS; DEPENDENT ASTHMATICS; CONTROLLED TRIAL; MILD ASTHMA; CORTICOSTEROIDS; MANAGEMENT;
Keywords:
asthma; asthma prevention and control; bronchial hyperreactivity; budesonide; drug administration schedule; randomized controlled trials;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Reddel, HK Royal Prince Alfred Hosp, Inst Resp Med, POB M77, Camperdown, NSW 2050, Australia Royal Prince Alfred Hosp POB M77 Camperdown NSW Australia 2050
Citazione:
H.K. Reddel et al., "Optimal asthma control, starting with high doses sf inhaled budesonide", EUR RESP J, 16(2), 2000, pp. 226-235

Abstract

The aim of this study was to determine whether outcomes in poorly controlled asthma can be further improved with a starting dose of inhaled budesonide higher than that recommended in international guidelines. The study had a parallel-group design and included 61 subjects with poorlycontrolled asthma, randomized to receive 3,200 mu g or 1,600 mu g budesonide daily by Turbuhaler(R) for 8 weeks (double-blind), then 1,600 mu g.day(-1) for 8 weeks (single-blind), followed by 14 months of open-label budesonide dose down-titration using a novel algorithm, with a written asthma crisis plan based on electronic peak expiratory flow monitoring. The primary outcome variable for weeks 1-16 was change in airway hyperresponsiveness (AHR), and, for the open-label phase, mean daily budesonide dose,By week 16, there were large changes from baseline in all outcomes, with no significant differences between the 3,200- and 1,600-mu g.day(-1) starting dose groups (AHR increased by 3.2 versus 3.0 doubling doses, p=0.7; morning peak flow increased by 134 versus 127 L.min(-1), p=0.8), Subjects starting with 3,200 mu g.day(-1) were 3.8 times more likely to achieve AHR withinthe normal range, as defined by a provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD20) of greater than or equal to 3.92 mu mol by week 16 (p=0.3), During dose titration, there wasno significant difference in mean budesonide dose (1,327 versus 1,325 mu g.day(-1), p>0.3). Optimal asthma control was achieved in the majority of subjects (at completion/withdrawal: median symptoms 0.0 days.week(-1), beta(2)-agonist use 0.2 occasions.day(-1), and PD20 2.4 mu mol). In subjects with poorly controlled asthma, a starting dose of 1,600 mu g.day(-1) budesonide was sufficient to lead to optimal control in most subjects. The high degree of control achieved, compared with previous studies, warrants further investigation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 03:09:04